Jyoti S. Mayadev, MD, Compares Efficacy of Durvalumab/CRT Vs Placebo/CRT in High-Risk Locally Advanced Cervical Cancer

Video

The 12-month progression-free survival rates among patients with high-risk locally advanced cervical cancer were comparable with durvalumab plus chemoradiotherapy vs placebo plus radiotherapy.

At the 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting, Jyoti S. Mayadev, MD, a radiation oncologist and professor of radiation medicine and applied sciences at the University of California San Diego School of Medicine, spoke with CancerNetwork® about key findings from the phase 3 CALLA trial (NCT03830866), assessing the addition of durvalumab (Infinzi) to chemoradiotherapy (CRT) vs placebo/CRT in patients with high-risk locally advanced cervical cancer.

The 12-month progression-free survival (PFS) rate was 76.0% for patients receiving durvalumab with CRT and 73.3% for those in the placebo arm. Additionally, the 24-month PFS rate was 65.9% in the durvalumab arm and 62.1% for those receiving placebo (HR, 0.84; 95% CI, 0.65-1.08; P = .174). Mayadev also discussed the trial’s international design and her takeaway from the subgroup analysis.

Transcript:

This was a global effort. We had more than 120 sites [in] 15 countries across the globe [and enrolled] patients with high-risk cervical cancer; these were truly high-risk patients. More than two-thirds had node-positive disease, and [had] stage IIIA/IVA disease. We randomized 770 patients in less than 2 years during a pandemic to CRT [and] durvalumab vs. placebo. Our primary objective was progression-free survival [PFS]. At 1 year, the PFS was no different between the durvalumab arm and the placebo arm. In terms of the hazard ratios in more granular detail, the 12-month PFS rate with the durvalumab/chemoradiation [arm] was 76.0% vs 73.3% with a placebo arm. At 24 months, the rate in durvalumab arm was 65.9% vs 62.1% with placebo. The hazard ratio was 0.84 and the P value was 0.174. We’ve presented the maturity at 31% at ASTRO 2022 as a plenary session. The median follow-up time was 18.5 months. In terms of the subgroup analysis, depending on the nodal status or the timeliness of radiation, there were no differences in terms of the durvalumab arm [vs the placebo arm].

Reference

Mayadev JS, Rong, Y, Toita T, et al. Durvalumab in combination with chemoradiotherapy (CRT) in locally advanced cervical cancer (LACC): radiotherapy (RT) delivery and subgroup analyses from CALLA. Presented at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting; October 23-26, 2022; San Antonio, TX; LBA 03. Accessed October 27, 2022.

Recent Videos
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
“Dendritic cell vaccines, CAR T-cell therapy, and things of that nature are holding some promise,” said Andrew Brenner, MD, PhD.
Related Content